What's Going on With Vera Therapeutics Stock on Tuesday?
Vera Therapeutics Phase 3 trial data show that Trutakna significantly reduces kidney disease progression in IgA nephropathy.
Stocks · News reference
Vera Therapeutics Announces TRUTAKNA Meets All Prespecified Endpoints Of Final Efficacy Analysis Of ORIGIN 3 Trial In Adults With Primary IgA Nephropathy At Risk For Disease Progression
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite kidney disease
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Vera Therapeutics shares are trading higher after the company announced that TRUTAKNA met all prespecified endpoints of the final efficacy analysis of the ORIGIN 3 trial in adults with primary IgA nephropathy at risk for disease progression.
8-K filing — Vera Therapeutics, Inc. (VERA)
Filed: 2026-09-15 AccNo: 0001193125-26-391280 Size: 11 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits